Evelo Biosciences, Inc. (OTCPK: EVLO)
Health Care · Biotechnology · US
$0.00
-99.00% today · -99.8% 1Y
Evelo Biosciences, Inc. (OTCPK: EVLO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $19.00 and employs 66 people.
Over the last twelve months the share price has lost 99.8%, trading between 0.00 and 0.00.
Tweenvest scores Evelo Biosciences, Inc. across four factors: quality 10/100. Its strongest factor is quality.
EVLO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $19.00
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -9.65
- Dividend yield
- —
- Beta (5Y)
- -25.23
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 18.98M
- Employees
- 66
- Next earnings
- —
About Evelo Biosciences, Inc.
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.
- ISIN
- US2997342025
- Founded
- 2014
- Listed since
- May 8, 2018
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €875.40 | +1.30% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.70 | +2.02% |
Figures last refreshed Aug 18, 2026.